Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Wopereis, Suzan ^a   Rubingh, Carina M ^a   Van Erk, Marjan J ^a   Verheij, Elwin R ^a   Van Vliet, Trinette ^a,c   Cnubben, Nicole H P ^a   Smilde, Age K ^a,b   Van Der Greef, Jan ^a   Van Ommen, Ben ^a   Hendriks, Henk F J ^a  

^a TNO   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Central Committee on Research Involving Human Subjects (CCMO)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; GLUTATHIONE METABOLISM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; METABOLITE; OBESITY; ORAL GLUCOSE TOLERANCE TEST;

EID: 84939895432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004525     Document Type: Article

References (51)

1. Hansson GK (2005) Mechanisms of disease: Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 352: 1685-1695+1626.
2. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: The link between insulin resistance, obesity and diabetes. Trends in Immunology 25: 4-7.
3. Fogarty AW, Glancy C, Jones S, Lewis SA, McKeever TM, et al. (2008) A prospective study of weight change and systemic inflammation over 9 y. American Journal of Clinical Nutrition 87: 30-35.
4. Bonassi S, Neri M, Puntoni R (2001) Validation of biomarkers as early predictors of disease. Mutat Res 480-481: 349-358.
5. Musaad S, Haynes EN (2007) Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev 29: 98-114.
6. Khuseyinova N, Koenig W (2006) Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care 12: 412-419.
7. Rajaram V, Pandhya S, Patel S, Meyer PM, Goldin M, et al. (2004) Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 93: 32C-48C.
8. He YD (2006) Genomic approach to biomarker identification and its recent applications. Cancer Biomark 2: 103-133.
9. Ginsburg GS, Haga SB (2006) Translating genomic biomarkers into clinically useful diagnostics. Expert Rev Mol Diagn 6: 179-191.
10. Wang SJ, Cohen N, Katz DA, Ruano G, Shaw PM, et al. (2006) Retrospective validation of genomic biomarkers-what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-workshop summary. Pharmacogenomics J 6: 82-88.
11. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.
12. Naylor S, Culbertson AW, Valentine SJ (2008) Towards a systems level analysis of health and nutrition. Current Opinion in Biotechnology 19: 100-109.
13. Yetukuri L, Katajamaa M, Medina-Gomez G, nen-Laakso T, Vidal-Puig A, et al. (2007) Bioinformatics strategies for lipidomics analysis: Characterization of obesity related hepatic steatosis. BMC Systems Biology 1: 12.
14. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, et al. (2008) Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4: 214.
15. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, et al. (2006) Largescale human metabolomics studies: A strategy for data (pre-) processing and validation. Analytical Chemistry 78: 567-574.
16. Verhoeckx KCM, Bijlsma S, Jespersen S, Ramaker R, Verheij ER, et al. (2004) Characterization of anti-inflammatory compounds using transcriptomics, proteomics, and metabolomics in combination with multivariate data analysis. International Immunopharmacology 4: 1499-1514.
17. Van Der Greef J, Martin S, Juhasz P, Adourian A, Plasterer T, et al. (2007) The art and practice of systems biology in medicine: Mapping patterns of relationships. Journal of Proteome Research 6: 1540-1559.
18. Clish CB, Davidov E, Oresic M, Plasterer TN, Lavine G, et al. (2004) Integrative Biological Analysis of the APOE∗3-Leiden Transgenic Mouse. OMICS A Journal of Integrative Biology 8: 3-13.
19. Van Der Greef J, Van Der Heijden R, Verheij E (2004) The role of mass spectrometry in systems biology: data processing and identification strategies in metabolomics. In: Advances in Mass Spectrometry. Ashcroft AE, Brenton G, Monaghen JJ, eds. Amsterdam: Elsevier Science. pp 145-165.
20. Koek MM, Muilwijk B, Van Der Werf MJ, Hankemeier T (2006) Microbial metabolomics with gas chromatography/mass spectrometry. Analytical Chemistry 78: 1272-1281.
21. Barker M, Rayens W (2003) Partial least squares for discrimination. Journal of Chemometrics 17: 166-173.
22. Martens H, Naes T (1989) Multivariate Calibration. Chichester, UK: John Wiley & Sons.
23. Dillon WR, Goldstein M (1984) Multivariate Analysis, Methods and Applications. New York, USA: John Wiley & Sons.
24. Joliffe IT (1986) Principal Component Analysis. New York, USA: Springer Verlag.
25. Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, et al. (1997) Handbook of Chemometrics and Qualimetrics. Amsterdam, the Netherlands: Part A. Elsevier.
26. Vandeginste BGM, Massart DL, Buydens LMC, De Jong S, Lewi PJ, et al. (1998) Handbook of Chemometrics and Qualimetrics. Amsterdam, the Netherlands: Part B. Elsevier.
27. Bro R (1996) Multiway calibration. Multilinear PLS. Journal of Chemometrics 10: 47-61.
28. Smilde AK (1997) Comments on Multilinear PLS. Journal of Chemometrics 11: 367-377.
29. Harshman RA, Lundy ME (1994) PARAFAC: Parallel Factor Analysis. Comput Stat Data Anal 18: 39-72.
30. Kiers HAL, Van Mechelen I (2001) Three-way component analysis: Principles and illustrative application. Psychological Methods 6: 84-110.
31. Smilde AK, Bro R, Geladi P (2004) Multi-way Analysis: Applications in the chemical sciences. West Sussex, UK: Wiley. pp 221-256.
32. Andersson CA, Bro R (2000) The N-way Toolbox for MATLAB. Chemom Intell Lab Syst 52: 1-4.
33. Boelsterli UA (2003) Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 192: 307-322.
34. Choi JS, Jin MJ, Han HK (2005) Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs. Journal of Pharmacy and Pharmacology 57: 1185-1189.
35. Mano Y, Usui T, Kamimura H (2005) In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharmaceutics and Drug Disposition 26: 35-39.
36. Masubuchi Y, Ose A, Horie T (2002) Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metabolism and Disposition 30: 1143-1148.
37. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, et al. (2005) Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Molecular Pharmacology 67: 1053-1066.
38. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, et al. (2004) Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metabolism and Disposition 32: 413-423.
39. Voilley N, De Weille J, Mamet J, Lazdunski M (2001) Nonsteroid antiinflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. Journal of Neuroscience 21: 8026-8033.
40. Wade LT, Kenna JG, Caldwell J (1997) Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chemical Research in Toxicology 10: 546-555.
41. Ware JA, Graf MLM, Martin BM, Lustberg LR, Pohl LR (1998) Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: Possible role in allergic reactions. Chemical Research in Toxicology 11: 164-171.
42. Becker MA, Jolly M (2006) Hyperuricemia and Associated Diseases. Rheumatic Disease Clinics of North America 32: 275-293.
43. Hayden MR, Tyagi SC (2004) Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutrition and Metabolism 1: 10.
44. Baker JF, Krishnan E, Chen L, Schumacher HR (2005) Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 118: 816-826.
45. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH (2005) Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45: 18-20.
46. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, et al. (2006) A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology-Renal Physiology 290: F625-F631.
47. Yu YM, Ryan CM, Fei ZW, Lu XM, Castillo L, et al. (2002) Plasma L-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely burned adult humans. American Journal of Physiology-Endocrinology and Metabolism 282: E247-E258.
48. Townsend DM, Tew KD, Tapiero H (2003) The importance of glutathione in human disease. Biomedicine and Pharmacotherapy 57: 145-155.
49. Lu SC (2000) Regulation of glutathione synthesis. Current topics in cellular regulation 36: 95-116.
50. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND (2004) Glutathione Metabolism and Its Implications for Health. Journal of Nutrition 134: 489-492.
51. Gonzalez-Ortiz M, Pascoe-Gonzalez S, Esperanzamartinez A, Kam-Ramos AM, Hernandez-Salazar E (2005) Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects. Metab Syndr Relat Disord 3: 95-101.